Ironwood Pharmaceuticals, Inc. - Class A Common Stock (NQ:IRWD)

4.050 -0.120 (-2.88%)

Streaming Delayed Price Updated: 10:56 AM EDT, Sep 9, 2026 Add to My Watchlist

Price and Volume

Volume	329,766
Open	4.140
Bid (Size)	4.050 (5,400)
Ask (Size)	4.060 (7,000)
Prev. Close	4.170
Today's Range	4.050 - 4.160
52wk Range	1.050 - 5.780
Shares Outstanding	160,028,388
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Ironwood Pharmaceuticals to Participate in the Wells Fargo 21st Annual Healthcare Conference

September 03, 2026

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

Ironwood Pharmaceuticals (NASDAQ:IRWD) Highlights Minervini Trend Template and High Growth Momentum ↗

August 26, 2026

Via Chartmill

Performance

YTD	-5.2%	-5.2%
1 Month	N/A	N/A
3 Month	+25.8%	+25.8%
6 Month	+9.5%	+9.5%
1 Year	+258.4%	+258.4%

More News

Ironwood (IRWD) Q2 2026 Earnings Call Transcript ↗

August 13, 2026

Via The Motley Fool

Ironwood Pharmaceuticals Q2 Earnings Call Highlights ↗

August 06, 2026

Via MarketBeat

Ironwood Pharmaceuticals (NASDAQ:IRWD) Raises Full-Year Guidance on Strong LINZESS Sales Despite Q2 Miss ↗

August 06, 2026

Via Chartmill

Ironwood Pharmaceuticals (NASDAQ:IRWD) Crushes Q1 Estimates with 97% LINZESS Surge ↗

May 07, 2026

Via Chartmill

Ironwood Pharmaceuticals Inc (NASDAQ:IRWD) Reports Q4 Miss but Provides Robust 2026 Outlook ↗

February 25, 2026

Via Chartmill

Ironwood Pharmaceuticals Raises 2026 Full-Year Financial Guidance Building on Strong Second Quarter Results

August 06, 2026

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

Ironwood Pharmaceuticals to Host Second Quarter 2026 Investor Update Call

July 30, 2026

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

Ironwood Appoints Dr. Jeffrey Silber Chief Medical Officer and Head of Research and Drug Development; STARS-2 Trial Initiated in June and Is Now Actively Recruiting Patients

July 14, 2026

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

July 07, 2026

Via Benzinga

Get insights into the top gainers and losers of Tuesday's after-hours session. ↗

July 07, 2026

Via Chartmill

Ironwood (IRWD) Q1 2026 Earnings Call Transcript ↗

June 01, 2026

Via The Motley Fool

Ironwood Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference

May 28, 2026

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

FDA Approves Use of LINZESS® (linaclotide) in Pediatric Patients Two Years of Age and Older with Functional Constipation (FC)

May 27, 2026

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

Ironwood Pharmaceuticals Reports Strong First Quarter 2026 Results With 97% Year-Over-Year LINZESS U.S. Net Sales Growth; Maintains Full-Year 2026 Financial Guidance

May 07, 2026

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

Ironwood Survey Findings at DDW 2026 Underscore Need for Therapies that Address Multiple Dimensions of Total Parenteral Nutrition (TPN) Burden in Short Bowel Syndrome (SBS)

May 04, 2026

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

Ironwood Pharmaceuticals to Host First Quarter 2026 Investor Update Call

April 30, 2026

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

Ironwood Pharmaceuticals to Share Real-World HCP Perspectives on Burden of Total Parenteral Nutrition in Short Bowel Syndrome (SBS) at Digestive Disease Week® 2026

April 23, 2026

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

Biohaven Stock Down 70% but One Fund's New $6 Million Bet Signals Turnaround Potential ↗

March 23, 2026

Via The Motley Fool

Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference

March 04, 2026

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

Here are the top movers in Wednesday's session. ↗

February 25, 2026

Via Chartmill

Ironwood (IRWD) Q4 2025 Earnings Call Transcript ↗

February 25, 2026

Via The Motley Fool

Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Results; Achieves 2025 Financial Guidance and Reiterates Strong 2026 Outlook

February 25, 2026

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2025 Investor Update Call

February 18, 2026

From Ironwood Pharmaceuticals, Inc.

Via Business Wire

Frequently Asked Questions

Is Ironwood Pharmaceuticals, Inc. - Class A Common Stock publicly traded?

Yes, Ironwood Pharmaceuticals, Inc. - Class A Common Stock is publicly traded.

What exchange does Ironwood Pharmaceuticals, Inc. - Class A Common Stock trade on?

Ironwood Pharmaceuticals, Inc. - Class A Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Ironwood Pharmaceuticals, Inc. - Class A Common Stock?

The ticker symbol for Ironwood Pharmaceuticals, Inc. - Class A Common Stock is IRWD on the Nasdaq Stock Market

What is the current price of Ironwood Pharmaceuticals, Inc. - Class A Common Stock?

The current price of Ironwood Pharmaceuticals, Inc. - Class A Common Stock is 4.050

When was Ironwood Pharmaceuticals, Inc. - Class A Common Stock last traded?

The last trade of Ironwood Pharmaceuticals, Inc. - Class A Common Stock was at 09/09/26 10:56 AM ET

What is the market capitalization of Ironwood Pharmaceuticals, Inc. - Class A Common Stock?

The market capitalization of Ironwood Pharmaceuticals, Inc. - Class A Common Stock is 648.11M

How many shares of Ironwood Pharmaceuticals, Inc. - Class A Common Stock are outstanding?

Ironwood Pharmaceuticals, Inc. - Class A Common Stock has 648M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.